Skip to main content
. 2018 Oct 25;11:1756286418805713. doi: 10.1177/1756286418805713

Figure 2.

Figure 2.

Radiological NEDA. Left panel: Percentage of patients treated with natalizumab (black bars) or fingolimod (grey bars) that achieved radiological NEDA at each timespan (T0–T1, T1–T2, T0–T2). *p < 0.05; Right panel: Survival curves demonstrating the risk of new/enlarging white matter lesions or gadolinium-enhancing lesions (natalizumab: black line, fingolimod: grey line).

NEDA, no evidence of disease activity.